According to CTI BioPharma
's latest financial reports the company's current revenue (TTM ) is A$0.12 Billion. In 2022 the company made a revenue of A$79.27 Million an increase over the revenue in the year 2021 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | A$0.11 B | 42.3% |
2022 | A$79.27 M | |
2021 | N/A | |
2020 | N/A | -100% |
2019 | A$4.77 M | -87.02% |
2018 | A$36.79 M | 14.24% |
2017 | A$32.2 M | -59.56% |
2016 | A$79.63 M | 259.99% |
2015 | A$22.12 M | -69.86% |
2014 | A$73.4 M | 88.82% |
2013 | A$38.87 M | |
2012 | N/A | |
2011 | N/A | -100% |
2010 | A$0.31 M | 252.64% |
2009 | A$0.08 M | -99.45% |
2008 | A$16.2 M | 11054.78% |
2007 | A$0.14 M | 43.14% |
2006 | A$0.1 M | -99.54% |
2005 | A$21.99 M | -42.49% |
2004 | A$38.24 M | 14.78% |
2003 | A$33.31 M | 11.1% |
2002 | A$29.98 M | 145.43% |
2001 | A$12.21 M | 1260.8% |
2000 | A$0.89 M | 96.68% |
1999 | A$0.45 M | -97.88% |
1998 | A$21.55 M | 19.03% |
1997 | A$18.11 M |